Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Cubist Pharmaceuticals Stories

2013-11-25 23:18:59

Senior Executives from Cubist Pharmaceuticals and Agensys join CHI Board LA JOLLA (PRWEB) November 25, 2013 California Healthcare Institute (CHI) announced today the election of two senior executives to serve on its board of directors: Robert Perez, MBA, President and Chief Operating Officer of Cubist Pharmaceuticals, and David Stover, Ph.D., Senior Vice President and Site Head of Agensys (a wholly owned subsidiary of Astellas). CHI is a nonprofit, public policy research organization,...

2013-11-07 08:34:03

PHILADELPHIA, Nov. 7, 2013 /PRNewswire/ -- TransCelerate BioPharma Inc. ("TransCelerate") is launching three new global initiatives to further advance efficiency in clinical trials and accelerate the development of new medicines: creation of common clinical trial protocol templates, development of clinical trial networks for pediatric and minority populations, and establishment of a global investigator registry. TransCelerate is also expanding two of its original five initiatives, the...

2013-10-01 08:27:18

NEW YORK, October 1, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Investors' Reports announced new research reports highlighting Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Halozyme Therapeutics, Inc. (NASDAQ: HALO), Taro Pharmaceutical Industries Ltd. (NYSE: TARO), Galena Biopharma, Inc. (NASDAQ: GALE) and Sequenom Inc. (NASDAQ: SQNM). Today's readers may access these reports free of charge - including full...

2013-09-30 08:26:21

NEW YORK, September 30, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Investors' Reports announced new research reports highlighting Abbott Laboratories (NYSE: ABT), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Pacific Biosciences of California (NASDAQ: PACB), Synageva BioPharma Corp. (NASDAQ: GEVA), and Oncothyreon Inc. (NASDAQ: ONTY). Today's readers may access these reports free of charge - including full...

2013-08-01 12:26:43

NEW YORK, Aug. 1, 2013 /PRNewswire/ -- Levi & Korsinsky is investigating the Board of Directors of Optimer Pharmaceuticals, Inc. ("Optimer" or the "Company") (NasdaqGS: OPTR) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Cubist Pharmaceuticals, Inc. (Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO ) Click here to learn more about the investigation...

2013-02-28 16:29:15

Optimer reports $62.4 million in DIFICID® (fidaxomicin) tablets net product sales for 2012 JERSEY CITY, N.J., Feb. 28, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today unaudited financial results for the fourth quarter and fiscal year ended December 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) Financial Highlights 2012 DIFICID net product sales in the U.S. and Canada of $62.4 million, compared to $21.5 million...

2013-02-27 08:29:08

COMPANY TO EXPLORE STRATEGIC ALTERNATIVES JERSEY CITY, N.J., Feb. 27, 2013 /PRNewswire/ -- The Board of Directors of Optimer Pharmaceuticals (NASDAQ: OPTR) (the "Company" or "Optimer") today announced the appointment of its Chairman, Dr. Henry McKinnell, as Chief Executive Officer. Dr. McKinnell was associated with Pfizer Inc., from 1971 until his retirement in 2007, including serving as Pfizer's Chief Executive Officer and Chairman from 2001 to 2006. The Board of Directors also...

2013-01-07 08:29:21

JERSEY CITY, N.J., Jan. 7, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today provided an update on 2012 sales for DIFICID (fidaxomicin) tablets, an antibacterial drug launched in July 2011 for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age or older in the United States. Preliminary 2012 gross product sales in the United States and Canada totaled $74.4 million. Preliminary gross product sales for the fourth quarter of 2012...

2009-12-10 06:30:00

SANTA MONICA, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Reprints Desk, Inc., a wholly owned subsidiary of Derycz Scientific, Inc. (OTC Bulletin Board: DYSC), has announced a collaboration with QUOSA Inc., to facilitate copyright-compliant article archiving and scientific literature re-use for Cubist Pharmaceuticals. Lexington MA-based Cubist becomes the first company to integrate Reprints Desk's scientific, technical, and medical (STM) Document Delivery service with QUOSA's Virtual...

2009-12-09 23:01:00

SANTA MONICA, Calif. and WALTHAM, Mass., Dec. 10 /PRNewswire/ -- Reprints Desk, Inc., and QUOSA, Inc., today announced that Cubist Pharmaceuticals has become the first shared customer to activate integration between Reprints Desk's STM Document Delivery service with QUOSA's Virtual Library, which facilitates copyright-compliant article archiving and scientific literature re-use. The integrated solution features integration with Rightsphere, the rights advisory and management tool from...